Business Wire

EUNETWORKS

7.12.2023 09:01:28 CET | Business Wire | Press release

Share
euNetworks’ CEO delivers insight at COP28 on the company’s sustainability focus

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, was recently featured in an interview series with leaders from across industries undertaken during the United Nations Climate Conference (COP28) in Dubai. The series of interviews captures lessons learned, sustainability success stories and key messages for the future from leaders across the energy, technology and telecom, manufacturing and finance industries. euNetworks has also released its latest Sustainability Report, detailing the company’s commitment to sustainability and substantial progress over the last year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231207410743/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Paula Cogan, CEO of euNetworks (Photo: Business Wire)

euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 17 cities and also operates a highly differentiated long haul network that spans 66,000 kilometres across 17 countries today. As a specialist in the sector, euNetworks continues to grow and invest in partnership with its customers, investing in new technologies and deepening its unique fibre network in Europe. The company is undertaking this growth with a strong focus on sustainability and has been working hard through 2023 to deliver tangible progress on its long-term sustainability goals.

“Throughout euNetworks’ history, we have remained dedicated to our core values, and our commitment to sustainability has never been stronger,” said Paula Cogan, Chief Executive Officer of euNetworks. “We understand the impact our operations can have on the environment, and we are committed to reducing our carbon footprint and contributing to global efforts in combatting climate change and transitioning to a low-carbon economy.”

COP28 has a focus on four paradigm shifts – fast-tracking the energy transition and slashing emissions before 2030; transforming climate finance by delivering on old promises and setting the framework for a new deal on finance; putting nature, people, lives, and livelihoods at the heart of climate action; and mobilising for the most inclusive COP ever. euNetworks’ efforts align with those shifts.

“Our pledge to be net-zero carbon by 2040 is not just an aspiration but a driving force behind our actions,” said Cogan. “We have joined the Climate Pledge, demonstrating our unwavering commitment to combat climate change. Setting 1.5°C-aligned science-based targets across Scopes 1, 2, and 3 is a testament to euNetworks’ ambition to be leaders in environmental responsibility in the digital infrastructure ecosystem. We shifted to renewable energy sources across our business, and we’ve reached our target of 98.8% today. We obtained a Sustainability Linked Loan in 2021 that enabled us to embed our commitment to sustainability by including ESG-linked KPIs into our financial framework. We are dedicated to pioneering innovation in carbon measurement tools for service and project-based emissions, empowering our customers to measure and address Scope 3 emissions with precision, and helping suppliers to reduce their carbon footprint. Our award-winning carbon tools are actively used in our operations and by our customers today. We aim to deliver the lowest carbon footprint per bit of data transmitted, which we take seriously and drives our daily efforts.”

euNetworks’ sustainability strategy, outlined in the company’s latest Sustainability Report, encompasses long-term objectives, focusing on carbon neutrality, a diverse, equitable, and inclusive workforce, responsible supply chain management, customer-driven innovation, and biodiversity conservation:

  • Net Zero: We have set our sights on achieving net-zero carbon emissions by 2040. This ambitious target involves increasing our use of renewable energy sources, implementing innovative technologies, and adopting efficient operational practices to minimise environmental impact.
  • Diverse, Equitable, and Inclusive workforce: We champion an inclusive culture that values the richness of our employees' backgrounds and perspectives. We prioritise building a diverse, equitable and inclusive culture, and our goal is to achieve gender balance in our workforce, positioning us as a preferred employer within the telecoms industry.
  • Responsible Supply Chain Management: We collaborate with our partners to establish responsible supply chain practices. This involves promoting transparency, ethical sourcing, and reducing our environmental footprint.
  • Customer-Focused Innovation: We are committed to ongoing innovation, developing bandwidth infrastructure solutions prioritising energy efficiency, emissions reduction, and circular economy principles.
  • Biodiversity Preservation: Our dedication extends to contributing to biodiversity conservation and ecosystem resilience. Our initiatives promote biodiversity awareness, protect natural habitats and support reforestation efforts.

“It’s clear that while euNetworks has made great progress towards its sustainability goals, we are still at the beginning of our journey,” said Cogan. “Collaboration among suppliers, customers, partners and the broader ecosystem will be essential to achieving substantial, long-term environmental change. In an industry fundamental to economies and society, euNetworks is committed to making significant sustainability strides of its own and supporting the bigger picture of businesses working together to solve the immense challenges of sustainability and climate change.”

To read euNetworks’ full Sustainability Report, go to https://eun.io/sustainability

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre-based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 518 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231207410743/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release

ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye